AI Tool Inventory for GMP: What QA Must Document Before Validation

Before a GMP team can validate an AI tool, it needs a defensible inventory of what exactly is being validated. That sounds obvious, but in practice many pharma manufacturers and CDMOs begin with a vendor demo, a pilot use case, or a user request for “an AI assistant for SOP questions” and only later try to formalize scope. By then, key validation decisions are already constrained by incomplete documentation. For QA, Validation, and CSV teams, the AI tool inventory is the foundation for intended use, system boundary, risk assessment, supplier evaluation, and ongoing change control.

In regulated environments, an “AI tool” is rarely a single application. It is usually a stack: user interface, identity and access layer, retrieval engine, large language model, source document repository, logging, infrastructure, and vendor-operated services. Under GAMP 5 Second Edition, that means the inventory must support a risk-based understanding of the full computerized system, not just the visible front end. Under EU GMP Annex 11, 21 CFR Part 11, and ICH Q10, QA must be able to show that intended use is defined, data flows are understood, records are controlled, suppliers are assessed, and changes are managed.

Why the AI inventory must come before validation

Validation cannot compensate for an undefined system. If your inventory is incomplete, your URS will be vague, your supplier questionnaire will miss critical controls, and your traceability matrix will map against assumptions instead of facts. That creates avoidable audit exposure.

For example, if a CDMO deploys an AI assistant to answer questions on cleaning validation SOPs, batch record procedures, and deviation workflows, QA needs to know:

• Whether the model is hosted by the vendor, by a hyperscaler in the EU, or on-premises
• Whether prompts and outputs are retained, and for how long
• Which document repositories are indexed and who approves inclusion
• Whether the tool only retrieves existing content or also generates summaries and recommendations
• Whether responses can influence GMP decisions, approvals, or record content
• Whether the system integrates with QMS, DMS, MES, LIMS, or ticketing platforms

Without that baseline inventory, it is impossible to determine whether the tool is GxP-relevant, which records fall under Part 11 or Annex 11 expectations, and what evidence is required for validation.

Practical rule: if QA cannot draw the system boundary on one page, validation has started too early.

What QA should include in an AI tool inventory

The inventory should be structured enough to support validation, but practical enough to maintain. For most GMP organizations, the following sections are the minimum useful starting point.

1. Business purpose and intended use

Start with the exact GMP-relevant purpose of the tool. Avoid generic descriptions such as “AI for compliance” or “chatbot for quality.” Instead document the intended use in operational terms.

• Business process supported: SOP lookup, deviation triage support, validation protocol search, training support, audit preparation
• User groups: QA, QC, validation engineers, production supervisors, IT, external auditors if applicable
• GxP relevance: direct, indirect, or non-GxP, with justification
• Permitted actions: answer questions from approved documents, provide citations, summarize procedures
• Prohibited actions: approve records, replace training, create uncontrolled GMP instructions, alter source data

This supports GAMP 5 intended use definition and creates the basis for risk assessment. It also helps prevent “scope creep,” where a tool validated for document Q&A gradually becomes used for decision support in deviations or CAPAs without corresponding controls.

2. System components and architecture

Inventory every component that materially affects output, security, or record integrity. In AI systems, hidden dependencies are common.

• User interface or chat application
• Authentication and authorization mechanism, such as SSO via Azure AD or Entra ID
• Retrieval layer and vector database
• Large language model provider and model version
• Document ingestion pipeline
• Source repositories, such as SharePoint, Veeva, OpenText, validated DMS, or network folders
• Logging and monitoring components
• Hosting environment, region, backup, and disaster recovery arrangement
• Administrative console and configuration tools

For DACH organizations, this is especially important where infrastructure may be split between internal IT, a Swiss hosting provider, Microsoft Azure EU regions, and a specialist AI vendor. QA needs visibility into all of it, because validation scope and supplier oversight depend on it.

3. Data types, source content, and record classification

Not all content in an AI tool has the same compliance significance. The inventory should classify what data enters, is processed by, and is generated from the system.

• Source documents: approved SOPs, validation plans, IQ/OQ/PQ protocols, work instructions, regulatory guidance, quality manuals
• Metadata: document status, version, effective date, owner, site applicability
• User input: prompts, free-text questions, copied excerpts from records
• System output: answers, citations, summaries, draft text
• Logs: user ID, timestamps, query history, feedback flags, admin changes

Then identify which of these qualify as electronic records under 21 CFR Part 11 and Annex 11. If outputs are merely transient informational responses, controls may differ from a system where AI-generated content is copied into deviations, CAPAs, or validation deliverables. QA should document that distinction explicitly.

4. Interfaces and data flows

An AI inventory should show where data comes from, where it goes, and what transformations occur. This is where many teams underestimate compliance impact.

For instance, if the tool ingests approved SOPs from a validated DMS but also indexes draft documents from a collaboration workspace, you have a document status control problem. If user prompts are forwarded to an external model API outside your approved region, you have a data transfer and supplier oversight problem. If outputs are copied into the QMS, you may have a GxP record creation and review problem.

• Inbound interfaces and ingestion frequency
• Document approval status checks before indexing
• Outbound interfaces or export functions
• API dependencies and third-party calls
• Data residency and cross-border transfer points

These elements are also relevant for EU AI Act readiness. Even where a pharma AI assistant is not a prohibited or high-risk AI system in the strict legal sense, organizations still need governance over transparency, logging, provider obligations, and deployment context.

5. Supplier and service model details

Under Annex 11 and ICH Q10, supplier assessment is not optional for critical systems. An AI inventory should identify all suppliers involved in service delivery, not just the contracting vendor.

• Primary vendor name and legal entity
• Sub-processors, model providers, cloud hosts, and monitoring providers
• SLA and support model
• Change notification commitments
• Security certifications and quality documentation available
• Backup, incident response, and business continuity responsibilities

For AI tools, QA should also document whether the vendor can change the underlying model, embeddings, ranking logic, or guardrails without customer approval. If that is possible, validation and change control must address it directly.

6. Configuration, roles, and administrative controls

Many AI compliance failures are configuration failures. The inventory should capture controllable settings and who can change them.

• Who can add or remove source documents
• Who can change prompt templates or system instructions
• Who can modify user roles and access rights
• Who can enable external connectors or export functions
• What audit trail exists for configuration changes

This supports Annex 11 expectations for access management and traceability, and informs the level of testing required during OQ.

7. Risk statements tied to GMP impact

The inventory should not replace risk assessment, but it should capture the obvious risk statements that validation must address. Typical examples include:

• Risk of responding from obsolete or draft SOPs
• Risk of hallucinated procedural steps without source support
• Risk of unauthorized access to quality documents
• Risk of unlogged configuration changes affecting output quality
• Risk of model or service changes by supplier without assessment

These are the bridge between the inventory and formal risk analysis under your CSV procedure.

A practical inventory format for QA and CSV teams

In most organizations, the most effective approach is a controlled inventory record linked to the validation plan. It does not need to be complex. A structured template in the QMS or validation document set is usually sufficient if it includes version control, ownership, approval, and review triggers.

A practical minimum set of fields includes:

• System name and unique ID
• Business owner, system owner, QA owner
• Intended use and process scope
• GxP classification and rationale
• Architecture summary and component list
• Interfaces and source repositories
• Record types and data classifications
• Suppliers and sub-processors
• Hosting region and retention settings
• Roles, admin privileges, and audit trail capabilities
• Known risks and linked validation deliverables

For multi-site DACH manufacturers and CDMOs, site applicability should also be documented. A tool used by one German manufacturing site for training support may have a different validation status than the same platform used at a Swiss quality hub for deviation support across multiple customers.

What inspectors and auditors will expect

Inspectors may not ask for an “AI inventory” by that exact name, but they will ask for the evidence it should contain. They will want to understand what the system does, where data comes from, who controls it, how changes are managed, and whether the validated state matches operational reality.

If QA can produce a current inventory that aligns with the URS, supplier assessment, risk assessment, and traceability matrix, the discussion becomes straightforward. If not, the organization often ends up explaining the system in fragments across IT, QA, and the vendor, which is exactly where contradictions appear.

For GMP AI tools, good validation starts with basic discipline: define the tool, define the boundary, define the records, and define the controls before writing test scripts. An AI inventory is not administrative overhead. It is the document that makes every later validation decision defensible.

See how ComplianceRAG handles AI Tool Inventory for GMP: What QA Must Document Before Validation for pharma and CDMO teams: See it in action →